SARMs Store sells research compounds only. Nothing on this page is medical advice or an instruction for human use.
Laxogenin is marketed as a plant-derived anabolic that works without touching the endocrine system. It is one of the few compounds in this category where the honest summary is short: the mechanism is plausible, the marketing is extensive, and the human evidence is essentially absent. This page sets out what is genuinely known, what is inferred from a single animal study on a related molecule, and why the analytical record on laxogenin-labelled supplements matters most of all.
What laxogenin is
Laxogenin is a steroidal sapogenin, specifically a spirostanol, first characterised from the rhizomes of Smilax species in the Japanese natural products literature of the 1960s and 1970s. It shares the four-ring core common to all steroids, but the side chain and substitution pattern are those of a plant sapogenin, not of testosterone or any androgen. It does not bind the human androgen receptor in any published work.
The compound sold in supplements is usually described as 5-alpha-hydroxy laxogenin, a hydroxylated derivative. This is where the first problem appears. 5-alpha-hydroxy laxogenin is not a well-characterised natural product with a substantial literature behind it; it entered the supplement market as a synthetic derivative around 2014, and the published chemistry on it is thin compared with the volume of marketing that followed.
Where the anabolic claim comes from
The marketing case rests almost entirely on analogy with brassinosteroids, a class of plant steroid hormones that regulate growth and stress response in plants and are structurally distinct from laxogenin. The key study is Esposito and colleagues, in the FASEB Journal in 2011, which examined homobrassinolide in rats and in cultured muscle cells. The authors reported increased protein synthesis, reduced protein degradation, increased lean body mass and food intake, and improved performance measures in treated rats, with signalling that appeared to run through the PI3K and Akt pathway rather than the androgen receptor.
That study is real, it is well conducted, and it is not a study of laxogenin. It used homobrassinolide, a different molecule. The reasoning that carries it across is: brassinosteroids are anabolic in rats, laxogenin is a plant steroid, therefore laxogenin is anabolic. That is an analogy, not evidence.
The older Japanese work on Smilax sapogenins, where laxogenin was first isolated, is phytochemical characterisation. It established structure and natural occurrence. It did not test anabolic effects in animals or humans.
What the human research shows
Nothing. There is no published randomised controlled trial of laxogenin or 5-alpha-hydroxy laxogenin in humans, no published pharmacokinetic study establishing oral bioavailability, and no published study of its effect on strength, lean mass, protein synthesis or recovery in people. Given that steroidal sapogenins of this type are known to be poorly absorbed orally, bioavailability is not a trivial question, and it has not been answered.
Anyone telling you what laxogenin does in humans is extrapolating from a rat study of a different compound, or repeating anecdote, or both.
The mislabelling problem
The most substantial body of actual data on laxogenin products concerns what is in the bottle. Independent analytical work has repeatedly found discrepancies between label and content: products containing far less of the claimed compound than stated, products where the material present was not the declared derivative, and products in which laxogenin was listed alongside or substituted with other unapproved ingredients. This mirrors the pattern established for the wider category by Van Wagoner and colleagues in JAMA in 2017, who found that fewer than half of products sold online as SARMs contained the compound named on the label.
The practical consequence is stark. If a product does not reliably contain what it says, even anecdotal reports about it cannot be attributed to laxogenin, because nobody knows what was actually consumed.
Side effects reported
Because there is no clinical trial record, there is no systematic safety data either. That is not the same as evidence of safety. The absence of androgen receptor binding means the endocrine effects associated with androgens are not expected in theory, and laxogenin is often marketed on that basis as requiring no post-cycle support. There are, however, isolated reports in the pharmacovigilance and hepatology literature of liver injury associated with multi-ingredient bodybuilding supplements that listed laxogenin among their ingredients, and in those cases causation cannot be attributed to any single component. The honest reading is that the human safety profile of laxogenin is unknown.
Comparison with related compounds
Laxogenin is frequently positioned as a non-hormonal alternative to prohormones such as Epistane or M-Sten, and to SARMs such as Ostarine. The comparison is asymmetric. Ostarine has phase I, II and III human data. Epistane and M-Sten have no efficacy trials but do have published case reports establishing that they do something measurable, unfortunately mostly to the liver. Laxogenin has neither efficacy trials nor a mechanism demonstrated in humans. It is also compared with ecdysterone, another plant steroid, which at least has a small human trial and a body of rodent work, though that literature is contested too.
Legal status in the UK, 2026
Laxogenin is not a controlled substance under the Misuse of Drugs Act 1971 and it is not a Class C anabolic steroid, because it is not an androgen. It is not an authorised medicine in the UK. Its status as a food supplement ingredient is not settled: a plant-derived compound with no history of significant consumption in Europe before May 1997 may fall within novel food rules, and synthetic derivatives such as 5-alpha-hydroxy laxogenin sit less comfortably still within food supplement frameworks. In practice UK suppliers sell it as a research compound, which is how SARMs Store handles it. Anyone relying on a particular classification should check the current MHRA and Food Standards Agency positions directly. Laxogenin is not named on the WADA Prohibited List, but athletes should note the mislabelling record above before assuming a product is clean.
How to check a supplier
For a compound with this much analytical uncertainty, verification is the entire story. Ask for a batch-specific certificate of analysis from an independent laboratory, with identity confirmed by HPLC or LC-MS rather than a simple assay, a stated purity figure, and a batch number matching the bottle. Check the label states the exact derivative, the amount per capsule and the capsule count, and carries a research-only notice. Dexterz Labs products in the cycle support range are made in the UK, and batch certificates of analysis are being published on the product page as testing is completed.
Frequently asked questions
Is laxogenin a steroid? It is a plant steroid in the chemical sense, a steroidal sapogenin. It is not an anabolic androgenic steroid and it does not bind the androgen receptor in published work.
What research supports laxogenin? No human research. The claims rest on a 2011 rat and cell study of homobrassinolide, a different molecule, published by Esposito and colleagues in the FASEB Journal.
Does laxogenin suppress testosterone? There is no evidence that it does and no mechanism by which it would, but no human study has measured it.
What is 5-alpha-hydroxy laxogenin? A synthetic hydroxylated derivative that entered the supplement market around 2014, with even less published characterisation than laxogenin itself.
Why do analyses of laxogenin supplements matter? Because independent testing has repeatedly found label and content do not match, so anecdotal reports cannot be attributed to the compound with any confidence.
Is laxogenin legal in the UK? It is not controlled and not a licensed medicine. Its food supplement status is unsettled, so it is sold here as a research compound only.
Related reading
- Do the studies support a PCT after SARMs?
- SARMs versus steroids and prohormones
- Epistane (methylepitiostanol) research guide
- Third-party testing: how to read a certificate of analysis
Research product line: PCT and cycle support research range
Sources
- Esposito D et al., FASEB J 2011;25:3708-3719 (homobrassinolide, rat and cell model). PubMed 21746867
- Van Wagoner RM et al., JAMA 2017;318:2004-2010. PubMed 29183075
- Japanese phytochemical literature on Smilax sapogenins, 1960s to 1970s.
- MHRA and Food Standards Agency guidance.